Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients

Clinical Immunology

Volumn 142, Issue 3, 2012, Pages 308-319

  Christophi, George P ^b,d   Gruber, Ross C ^a,c   Panos, Michael ^a   Christophi, Rebecca L ^b   Jubelt, Burk ^a,b   Massa, Paul T ^a,b  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Astrocytes; Autoimmunity; Demyelination; EAE; IL 33; Inflammation

Indexed keywords

BETA1A INTERFERON; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 13; INTERLEUKIN 33; INTERLEUKIN 6;

ADULT; ARTICLE; ASTROCYTE; BLOOD LEVEL; CELLULAR DISTRIBUTION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; LYMPHOCYTE CULTURE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; UPREGULATION; WHITE MATTER;

ADULT; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM; FEMALE; HUMANS; INTERLEUKINS; LYMPHOCYTES; MACROPHAGES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NF-KAPPA B; UP-REGULATION;

EID: 84857370530     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.11.007     Document Type: Article

References (94)

1. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 2000, 343(13):938-952.
2. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47(6):707-717.
3. Kornek B., Lassmann H. Neuropathology of multiple sclerosis-new concepts. Brain Res. Bull. 2003, 61(3):321-326.
4. Eggert M., Goertsches R., Seeck U., Dilk S., Neeck G., Zettl U.K. Changes in the activation level of NF-kappa B in lymphocytes of MS patients during glucocorticoid pulse therapy. J. Neurol. Sci. 2008, 264(1-2):145-150.
5. Gobin S.J., Montagne L., Van Zutphen M., Van Der Valk P., Van Den Elsen P.J., De Groot C.J. Upregulation of transcription factors controlling MHC expression in multiple sclerosis lesions. Glia 2001, 36(1):68-77.
6. Frisullo G., Angelucci F., Caggiula M., Nociti V., Iorio R., Patanella A.K., et al. pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity. J. Neurosci. Res. 2006, 84(5):1027-1036.
7. Feng X., Petraglia A.L., Chen M., Byskosh P.V., Boos M.D., Reder A.T. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J. Neuroimmunol. 2002, 129(1-2):205-215.
8. Zeis T., Graumann U., Reynolds R., Schaeren-Wiemers N. Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection. Brain 2008, 131(Pt 1):288-303.
9. Cannella B., Raine C.S. Multiple sclerosis: cytokine receptors on oligodendrocytes predict innate regulation. Ann. Neurol. 2004, 55(1):46-57.
10. Christophi G.P., Hudson C.A., Gruber R.C., Christophi C.P., Mihai C., Mejico L.J., et al. SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients. Lab. Invest. 2008, 88(3):243-255.
11. Dogan R.N., Karpus W.J. Chemokines and chemokine receptors in autoimmune encephalomyelitis as a model for central nervous system inflammatory disease regulation. Front. Biosci. 2004, 9:1500-1505.
12. Ubogu E.E., Cossoy M.B., Ransohoff R.M. The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol. Sci. 2006, 27(1):48-55.
13. Hendriks J.J., Teunissen C.E., de Vries H.E., Dijkstra C.D. Macrophages and neurodegeneration. Brain Res. Brain Res. Rev. 2005, 48(2):185-195.
14. Rodriguez M. Effectors of demyelination and remyelination in the CNS: implications for multiple sclerosis. Brain Pathol. 2007, 17(2):219-229.
15. Scarisbrick I.A., Linbo R., Vandell A.G., Keegan M., Blaber S.I., Blaber M., et al. Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. Biol. Chem. 2008, 389(6):739-745.
16. Scarisbrick I.A., Blaber S.I., Lucchinetti C.F., Genain C.P., Blaber M., Rodriguez M. Activity of a newly identified serine protease in CNS demyelination. Brain 2002, 125(Pt 6):1283-1296.
17. Karpus W.J., Kennedy K.J., Fife B.T., Bennett J.L., Dal Canto M.C., Kunkel S.L., et al. Anti-CCL2 treatment inhibits Theiler's murine encephalomyelitis virus-induced demyelinating disease. J. Neurovirol. 2006, 12(4):251-261.
18. Liew F.Y., Pitman N.I., McInnes I.B. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 2010, 10(2):103-110.
19. Kurowska-Stolarska M., Hueber A., Stolarski B., McInnes I.B. Interleukin-33: a novel mediator with a role in distinct disease pathologies. J. Intern. Med. 2011, 269(1):29-35.
20. Theoharides T.C., Zhang B., Kempuraj D., Tagen M., Vasiadi M., Angelidou A., et al. IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(9):4448-4453.
21. Funakoshi-Tago M., Tago K., Hayakawa M., Tominaga S., Ohshio T., Sonoda Y., et al. TRAF6 is a critical signal transducer in IL-33 signaling pathway. Cell. Signal. 2008, 20(9):1679-1686.
22. Zhang L., Lu R., Zhao G., Pflugfelder S.C., Li D.Q. TLR-mediated induction of pro-allergic cytokine IL-33 in ocular mucosal epithelium. Int. J. Biochem. Cell Biol. 2011, 43(9):1383-1391.
23. Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23(5):479-490.
24. Nile C.J., Barksby E., Jitprasertwong P., Preshaw P.M., Taylor J.J. Expression and regulation of interleukin-33 in human monocytes. Immunology 2010, 130(2):172-180.
25. Funakoshi-Tago M., Tago K., Sato Y., Tominaga S., Kasahara T. JAK2 is an important signal transducer in IL-33-induced NF-kappaB activation. Cell. Signal. 2011, 23(2):363-370.
26. Espinassous Q., Garcia-de-Paco E., Garcia-Verdugo I., Synguelakis M., von Aulock S., Sallenave J.M., et al. IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex. J. Immunol. 2009, 183(2):1446-1455.
27. Turnquist H.R., Thomson A.W. IL-33 broadens its repertoire to affect DC. Eur. J. Immunol. 2009, 39(12):3292-3295.
28. Aoki S., Hayakawa M., Ozaki H., Takezako N., Obata H., Ibaraki N., et al. ST2 gene expression is proliferation-dependent and its ligand, IL-33, induces inflammatory reaction in endothelial cells. Mol. Cell. Biochem. 2010, 335(1-2):75-81.
29. Guo L., Wei G., Zhu J., Liao W., Leonard W.J., Zhao K., et al. IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(32):13463-13468.
30. Oboki K., Ohno T., Kajiwara N., Arae K., Morita H., Ishii A., et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(43):18581-18586.
31. Volarevic V., Mitrovic M., Milovanovic M., Zelen I., Nikolic I., Mitrovic S., et al. Protective role of IL-33/ST2 axis in Con A-induced hepatitis. J. Hepatol. 2012, 56(1):26-33.
32. Smith D.E. The biological paths of IL-1 family members IL-18 and IL-33. J. Leukoc. Biol. 2010, 89(3):383-392.
33. Hudson C.A., Christophi G.P., Gruber R.C., Wilmore J.R., Lawrence D.A., Massa P.T. Induction of IL-33 expression and activity in central nervous system glia. J. Leukoc. Biol. 2008, 84(3):631-643.
34. Yasuoka S., Kawanokuchi J., Parajuli B., Jin S., Doi Y., Noda M., et al. Production and functions of IL-33 in the central nervous system. Brain Res. 2011, 1385:8-17.
35. Chakraborty S., Kaushik D.K., Gupta M., Basu A. Inflammasome signaling at the heart of central nervous system pathology. J. Neurosci. Res. 2010, 88(8):1615-1631.
36. Theoharides T.C., Alysandratos K.D., Angelidou A., Delivanis D.A., Sismanopoulos N., Zhang B., et al. Mast cells and inflammation. Biochim. Biophys. Acta 2012, 1822:21-33.
37. Theoharides T.C., Kempuraj D., Kourelis T., Manola A. Human mast cells stimulate activated T cells: implications for multiple sclerosis. Ann. N. Y. Acad. Sci. 2008, 1144:74-82.
38. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50(1):121-127.
39. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998, 352(9139):1498-1504.
40. Massa P.T., Wu H. Interferon regulatory factor element and interferon regulatory factor 1 in the induction of major histocompatibility complex class I genes in neural cells. J. Interferon Cytokine Res. 1995, 15(9):799-810.
41. Chang L., Gusewitch G.A., Chritton D.B., Folz J.C., Lebeck L.K., Nehlsen-Cannarella S.L. Rapid flow cytometric assay for the assessment of natural killer cell activity. J. Immunol. Methods 1993, 166(1):45-54.
42. De Nichilo M.O., Burns G.F. Granulocyte-macrophage and macrophage colony-stimulating factors differentially regulate alpha v integrin expression on cultured human macrophages. Proc. Natl. Acad. Sci. U. S. A. 1993, 90(6):2517-2521.
43. Blystone S.D., Graham I.L., Lindberg F.P., Brown E.J. Integrin alpha v beta 3 differentially regulates adhesive and phagocytic functions of the fibronectin receptor alpha 5 beta 1. J. Cell Biol. 1994, 127(4):1129-1137.
44. Christophi G.P., Hudson C.A., Gruber R., Christophi C.P., Massa P.T. Promoter-specific induction of the phosphatase SHP-1 by viral infection and cytokines in CNS glia. J. Neurochem. 2008, 105:2511-2523.
45. Krissansen G.W., Elliott M.J., Lucas C.M., Stomski F.C., Berndt M.C., Cheresh D.A., et al. Identification of a novel integrin beta subunit expressed on cultured monocytes (macrophages). Evidence that one alpha subunit can associate with multiple beta subunits. J. Biol. Chem. 1990, 265(2):823-830.
46. Atz M., Walsh D., Cartagena P., Li J., Evans S., Choudary P., et al. Methodological considerations for gene expression profiling of human brain. J. Neurosci. Methods 2007, 163(2):295-309.
47. Christophi G.P., Isackson P.J., Blaber S., Blaber M., Rodriguez M., Scarisbrick I.A. Distinct promoters regulate tissue-specific and differential expression of kallikrein 6 in CNS demyelinating disease. J. Neurochem. 2004, 91(6):1439-1449.
48. Renard P., Ernest I., Houbion A., Art M., Le Calvez H., Raes M., et al. Development of a sensitive multi-well colorimetric assay for active NFkappaB. Nucleic Acids Res. 2001, 29(4):E21.
49. Zhu L., Zou W., Yu C., Lin J., He X. Human recombinant PLD2 can repress p65 activity of guinea pigs of chronic asthma in vivo. Cell. Mol. Immunol. 2006, 3(4):307-310.
50. Sun J., Ramnath R.D., Tamizhselvi R., Bhatia M. Neurokinin A engages neurokinin-1 receptor to induce NF-kappaB-dependent gene expression in murine macrophages: implications of ERK1/2 and PI 3-kinase/Akt pathways. Am. J. Physiol. Cell Physiol. 2008, 295(3):C679-C691.
51. Massa P.T., Wu C. Increased inducible activation of NF-kappaB and responsive genes in astrocytes deficient in the protein tyrosine phosphatase SHP-1. J. Interferon Cytokine Res. 1998, 18(7):499-507.
52. Link H. The cytokine storm in multiple sclerosis. Mult. Scler. 1998, 4(1):12-15.
53. Hohnoki K., Inoue A., Koh C.S. Elevated serum levels of IFN-gamma, IL-4 and TNF-alpha/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage. J. Neuroimmunol. 1998, 87(1-2):27-32.
54. Christophi G., Panos M., Hudson C., Mihai C., Jubelt B., Massa P. Interferon-b treatment in multiple sclerosis attenuates inflammatory gene expression through inducible activity of the phosphatase SHP-1. Clin. Immunol. 2009, 133(1):27-44.
55. Christophi G.P., Hudson C.A., Panos M., Gruber R.C., Massa P.T. Modulation of macrophage infiltration and inflammatory activity by the phosphatase SHP-1 in virus-induced demyelinating disease. J. Virol. 2009, 83(2):522-539.
56. Ohno T., Oboki K., Morita H., Kajiwara N., Arae K., Tanaka S., et al. Paracrine IL-33 stimulation enhances lipopolysaccharide-mediated macrophage activation. PLoS One 2011, 6(4):e18404.
57. Massa P.T., Aleyasin H., Park D.S., Mao X., Barger S.W. NFkappaB in neurons? The uncertainty principle in neurobiology. J. Neurochem. 2006, 97(3):607-618.
58. Yan J., Greer J.M. NF-kappa B, a potential therapeutic target for the treatment of multiple sclerosis. CNS Neurol. Disord. Drug Targets 2008, 7(6):536-557.
59. Gross O., Thomas C.J., Guarda G., Tschopp J. The inflammasome: an integrated view. Immunol. Rev. 2011, 243(1):136-151.
60. Lamkanfi M., Dixit V.M. Modulation of inflammasome pathways by bacterial and viral pathogens. J. Immunol. 2011, 187(2):597-602.
61. Lamkanfi M., Dixit V.M. IL-33 raises alarm. Immunity 2009, 31(1):5-7.
62. Luthi A.U., Cullen S.P., McNeela E.A., Duriez P.J., Afonina I.S., Sheridan C., et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 2009, 31(1):84-98.
63. Oboki K., Nakae S., Matsumoto K., Saito H. IL-33 and airway inflammation. Allergy Asthma Immunol. Res. 2011, 3(2):81-88.
64. Stolarski B., Kurowska-Stolarska M., Kewin P., Xu D., Liew F.Y. IL-33 exacerbates eosinophil-mediated airway inflammation. J. Immunol. 2010, 185(6):3472-3480.
65. Louten J., Rankin A.L., Li Y., Murphy E.E., Beaumont M., Moon C., et al. Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation. Int. Immunol. 2011, 23(5):307-315.
66. Hermans G., Stinissen P., Hauben L., Van den Berg-Loonen E., Raus J., Zhang J. Cytokine profile of myelin basic protein-reactive T cells in multiple sclerosis and healthy individuals. Ann. Neurol. 1997, 42(1):18-27.
67. Secor V.H., Secor W.E., Gutekunst C.A., Brown M.A. Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J. Exp. Med. 2000, 191(5):813-822.
68. Xu D., Jiang H.R., Kewin P., Li Y., Mu R., Fraser A.R., et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(31):10913-10918.
69. Sayed B.A., Walker M.E., Brown M.A. Cutting edge: mast cells regulate disease severity in a relapsing-remitting model of multiple sclerosis. J. Immunol. 2011, 186(6):3294-3298.
70. Komai-Koma M., Xu D., Li Y., McKenzie A.N., McInnes I.B., Liew F.Y. IL-33 is a chemoattractant for human Th2 cells. Eur. J. Immunol. 2007, 37(10):2779-2786.
71. Iikura M., Suto H., Kajiwara N., Oboki K., Ohno T., Okayama Y., et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab. Invest. 2007, 87(10):971-978.
72. Breij E.C., Brink B.P., Veerhuis R., van den Berg C., Vloet R., Yan R., et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann. Neurol. 2008, 63(1):16-25.
73. Christophi G.P., Panos M., Hudson C.A., Christophi R.L., Gruber R.C., Mersich A.T., et al. Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype. Lab. Invest. 2009, 89(7):742-759.
74. Joshi A.D., Oak S.R., Hartigan A.J., Finn W.G., Kunkel S.L., Duffy K.E., et al. Interleukin-33 contributes to both M1 and M2 chemokine marker expression in human macrophages. BMC Immunol. 2010, 11:52.
75. Kurowska-Stolarska M., Stolarski B., Kewin P., Murphy G., Corrigan C.J., Ying S., et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J. Immunol. 2009, 183(10):6469-6477.
76. Andre R., Lerouet D., Kimber I., Pinteaux E., Rothwell N.J. Regulation of expression of the novel IL-1 receptor family members in the mouse brain. J. Neurochem. 2005, 95(2):324-330.
77. Jack C., Ruffini F., Bar-Or A., Antel J.P. Microglia and multiple sclerosis. J. Neurosci. Res. 2005, 81(3):363-373.
78. Chang Y.J., Kim H.Y., Albacker L.A., Baumgarth N., McKenzie A.N., Smith D.E., et al. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat. Immunol. 2011, 12(7):631-638.
79. Lipton H.L., Liang Z., Hertzler S., Son K.N. A specific viral cause of multiple sclerosis: one virus, one disease. Ann. Neurol. 2007, 61(6):514-523.
80. Poeck H., Bscheider M., Gross O., Finger K., Roth S., Rebsamen M., et al. Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production. Nat. Immunol. 2010, 11(1):63-69.
81. Rathinam V.A., Jiang Z., Waggoner S.N., Sharma S., Cole L.E., Waggoner L., et al. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat. Immunol. 2010, 11(5):395-402.
82. Pang I.K., Iwasaki A. Inflammasomes as mediators of immunity against influenza virus. Trends Immunol. 2011, 32(1):34-41.
83. Rajan J.V., Rodriguez D., Miao E.A., Aderem A. The NLRP3 inflammasome detects encephalomyocarditis virus and vesicular stomatitis virus infection. J. Virol. 2011, 85(9):4167-4172.
84. Delarasse C., Gonnord P., Galante M., Auger R., Daniel H., Motta I., et al. Neural progenitor cell death is induced by extracellular ATP via ligation of P2X7 receptor. J. Neurochem. 2009, 109(3):846-857.
85. Domercq M., Perez-Samartin A., Aparicio D., Alberdi E., Pampliega O., Matute C. P2X7 receptors mediate ischemic damage to oligodendrocytes. Glia 2010, 58(6):730-740.
86. Marina-Garcia N., Franchi L., Kim Y.G., Miller D., McDonald C., Boons G.J., et al. Pannexin-1-mediated intracellular delivery of muramyl dipeptide induces caspase-1 activation via cryopyrin/NLRP3 independently of Nod2. J. Immunol. 2008, 180(6):4050-4057.
87. Kanneganti T.D., Lamkanfi M., Kim Y.G., Chen G., Park J.H., Franchi L., et al. Pannexin-1-mediated recognition of bacterial molecules activates the cryopyrin inflammasome independent of Toll-like receptor signaling. Immunity 2007, 26(4):433-443.
88. Allakhverdi Z., Smith D.E., Comeau M.R., Delespesse G. Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J. Immunol. 2007, 179(4):2051-2054.
89. Enoksson M., Lyberg K., Moller-Westerberg C., Fallon P.G., Nilsson G., Lunderius-Andersson C. Mast cells as sensors of cell injury through IL-33 recognition. J. Immunol. 2011, 186(4):2523-2528.
90. Gregory G.D., Robbie-Ryan M., Secor V.H., Sabatino J.J., Brown M.A. Mast cells are required for optimal autoreactive T cell responses in a murine model of multiple sclerosis. Eur. J. Immunol. 2005, 35(12):3478-3486.
91. Theoharides T.C., Kempuraj D., Iliopoulou B.P. Mast cells, T cells, and inhibition by luteolin: implications for the pathogenesis and treatment of multiple sclerosis. Adv. Exp. Med. Biol. 2007, 601:423-430.
92. Cannella B., Raine C.S. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 1995, 37:424-435. [see comments].
93. Nile C.J., Barksby E., Jitprasertwong P., Preshaw P.M., Taylor J.J. Expression and regulation of interleukin-33 in human monocytes. Immunology 2010, 130:172-180.
94. Ali S., Mohs A., Thomas M., Klare J., Ross R., Schmitz M.L., et al. The dual function cytokine IL-33 interacts with the transcription factor NF-kappaB to dampen NF-kappaB-stimulated gene transcription. J. Immunol. 2011, 187(4):1609-1616.